Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of the National Cancer Institute

• Publication date

  2005-05-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/DJI114PMID 15870437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• North America

  2022cited by this paper
• Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

  2004cited by this paper
• Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer

  2004cited by this paper
• Early versus late chest radiotherapy for limited stage small cell lung cancer.

  2004cited by this paper
• Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: A randomised, controlled trial

  2004cited by this paper
• Effect of autologous salvaged blood on postoperative natural killer cell precursor frequency.

  2004cited by this paper
• O-276 A single center, controlled study of standard versus dose intensified chemotherapyy with sequential reinfusion of haematopoetic progenitor cells in small cell lung cancer: final results

  2003cited by this paper
• O-68 Long term results of a phase III trial comparing once a day radiotherapy (qd RT) or twice a day radiotherapy (bid RT) in limited stage small cell lung cancer (LSCLC)

  2003cited by this paper
• O-73 High dose, twice-daily thoracic radiotherapy (TRT) with daily chemotherapy in limited stage small cell lung cancer

  2003cited by this paper
• O-69 A randomized study of timing of thoracic irradiation in small cell lung cancer (SCLC) — study 8

  2003cited by this paper
• O-275 Ifosfamide, carboplatin and etoposide with mid-cycle vincristine (ICE-V) versus standard chemotherapy (C) in patients with small cell lung cancer (SCLC) and good performance status (PS): results of an MRC randomized trial (LU21)

  2003cited by this paper
• Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

  2002cited by this paper
• Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

  2002cited by this paper
• Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.

  2002cited by this paper
• Outpatient intensive chemotherapy for small cell lung cancer: five years experience of modified 'ICE' ifosfamide carboplatin and etoposide.

  2002cited by this paper
• Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America

  2002cited by this paper
• Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.

  2001cited by this paper
• Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

  2000cited by this paper
• Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer

  2000cited by this paper
• Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.

  1999cited by this paper
• Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.

  1999cited by this paper
• Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group.

  1999cited by this paper
• Review of selected randomized trials in small cell lung cancer.

  1998cited by this paper
• Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.

  1998cited by this paper
• Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

  1998cited by this paper
• Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group.

  1997cited by this paper
• 234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study

  1997cited by this paper
• 793 Five day oral etoposide treatment for advanced small cell lung cancer (SCLC): Quality of life (QOL) assessment in a randomised comparison with intravenous chemotherapy

  1997cited by this paper
• Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.

  1997cited by this paper
• Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study.

  1997cited by this paper
• CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.

  1997cited by this paper
• Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.

  1997cited by this paper
• Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.

  1996cited by this paper
• A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial.

  1996cited by this paper
• Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood.

  1995cited by this paper
• Chemotherapy with vincristine/ifosfamide/carboplatin/etoposide in small cell lung cancer.

  1995cited by this paper
• Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.

  1995cited by this paper
• Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission.

  1995cited by this paper
• Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer :f a randomized phase III study

  1994cited by this paper
• Viability of haemopoietic progenitors from whole blood, bone marrow and leukapheresis product: effects of storage media, temperature and time.

  1994cited by this paper
• Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.

  1994cited by this paper
• Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

  1994cited by this paper
• Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

  1993cited by this paper
• Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

  1993cited by this paper
• Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer.

  1993cited by this paper
• Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.

  1993cited by this paper
• A meta-analysis of thoracic radiotherapy for small-cell lung cancer.

  1992cited by this paper
• Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group.

  1992cited by this paper
• Phase II and III studies with carboplatin in small cell lung cancer.

  1992cited by this paper
• A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.

  1991cited by this paper
• Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

  1991cited by this paper
• Carboplatin in small cell lung cancer.

  1990cited by this paper
• A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group.

  1990cited by this paper
• Duration of chemotherapy in small cell lung cancer.

  1990cited by this paper
• Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.

  1989cited by this paper
• The pathophysiology and staging of cutaneous malignant melanoma.

  1989cited by this paper
• Staging and prognostic factors in small cell lung cancer: a consensus report

  1989cited by this paper
• Review of therapeutic trials of carboplatin in lung cancer.

  1989cited by this paper
• Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

  1989cited by this paper
• Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients

  1987cited by this paper
• Staging and prognostic factors in small cell carcinoma of the lung.

  1983cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1982cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper
• Intensive chemotherapy of small cell bronchogenic carcinoma.

  1977cited by this paper

• Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study

  2024cites this paper
• Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.

  2024cites this paper
• Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review

  2022cites this paper
• Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors

  2021cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• Chemotherapy for Small Cell Lung Cancer 58

  2018cites this paper
• Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.

  2017cites this paper
• Small Split Doses of CD34+ Peripheral Blood Stem Cells to Support Repeated Cycles of Nonmyeloablative Chemotherapy

  2017cites this paper
• 蟾蝓保元汤为主治疗晚期非小细胞肺癌的队列研究 A Cohort Study on Advanced-Stage NSCLC Mainly with Chanyubaoyuan Decoction

  2014cites this paper
• Advances in pharmacotherapy of small cell lung cancer

  2014cites this paper
• A Cohort Study on Advanced-Stage NSCLC Mainly with Chanyubaoyuan Decoction

  2014cites this paper
• Small cell lung cancer: therapies and targets.

  2014cites this paper
• Cancer of the Lung: Non–Small Cell Lung Cancer and Small Cell Lung Cancer

  2014cites this paper
• Cancers bronchiques à petites cellules étendus Traitement standard et nouvelles approches thérapeutiques

  2014cites this paper
• Systemic therapy for small cell lung cancer.

  2013cites this paper
• Management of Lung Cancer in Older People

  2013cites this paper
• Chemotherapy in the Elderly: Standard Chemotherapy or Specific Regimens?

  2013cites this paper
• Modern Management of Small-Cell Lung Cancer

  2012cites this paper
• Chemoradiotherapy in limited-disease small-cell lung cancer

  2012cites this paper
• 15 – Malignome des Respirationstrakts

  2012cites this paper
• Practice Guidelines for the Use of rHuG-CSF in an Oncology Setting

  2012cites this paper
• Chemotherapy for small cell lung cancer: a comprehensive review

  2012cites this paper
• Novel Therapies for the Treatment of Small-Cell Lung Cancer

  2012cites this paper
• Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study

  2012cites this paper
• Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour

  2011cites this paper
• Small cell lung cancer.

  2011cites this paper
• Rola przeszczepiania autologicznych krwiotwórczych komórek macierzystych w leczeniu guzów litych

  2011cites this paper
• Analyse critique des stratégies thérapeutiques du cancer à petites cellules

  2011cites this paper
• Treatment of limited small cell lung cancer: an old or new challenge?

  2011cites this paper
• 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

  2011cites this paper
• Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cites this paper
• Treatment of extensive-stage small cell lung carcinoma: current status and future prospects

  2010cites this paper
• Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms

  2010cites this paper
• Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy

  2010cites this paper
• The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit.

  2010cites this paper
• Small cell lung cancer

  2010cites this paper
• Lung cancer.

  2010cites this paper
• Camptothecins Compared with Etoposide in Combination with Platinum Analog in Extensive Stage Small Cell Lung Cancer: Systematic Review with Meta-Analysis

  2010cites this paper
• Small Cell Carcinoma of the Lung

  2010cites this paper
• Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

  2010cites this paper
• Impact of high-dose chemotherapy with autologous hematopoietic stem cell transplantation on small-cell lung cancer.

  2009cites this paper
• Lung cancer.

  2009cites this paper
• Influence of Time Factor and Repopulation on Treatment Resistance

  2009cites this paper
• Efficacy of intensified chemotherapy with hematopoietic progenitors in small-cell lung cancer: A meta-analysis of the published literature.

  2009cites this paper
• Hochdosistherapie und molekulare Therapie beim kleinzelligen Lungenkarzinom

  2008cites this paper
• Long-Term Survival of a Patient with Small Cell Lung Cancer after Nine Lines of Chemotherapy and Radiation

  2008cites this paper
• Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

  2008cites this paper
• Small cell lung cancer.

  2008cites this paper
• A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.

  2008cites this paper
• Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430

  2008cites this paper
• Current status of clinical trials for small cell lung cancer.

  2008cites this paper
• High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults.

  2007cites this paper
• Design of new oxazaphosphorine anticancer drugs.

  2007cites this paper
• An extended dosing regimen of epoetin alfa 60,000 units every 2 weeks in anemic patients with cancer receiving chemotherapy.

  2007cites this paper
• Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses.

  2007cites this paper
• High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review.

  2007cites this paper
• Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

  2007cites this paper
• Small Cell Lung Cancer (SCLC); any progress?

  2007cites this paper
• European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: IV. Limited disease.

  2007cites this paper
• Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable Prognosis

  2007cites this paper
• Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.

  2007cites this paper
• Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.

  2007cites this paper
• Les cancers à petites cellules (CPC). Prise en charge thérapeutique

  2006cites this paper
• KAPITEL 15 – Malignome des Respirationstrakts

  2006cites this paper
• Management of small cell lung cancer

  2006cites this paper
• Dose and outcome: the hurdle of neutropenia (Review).

  2006cites this paper
• Clinical Pharmacology of Cyclophosphamide and Ifosfamide

  2006influential citation
• Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.

  2006cites this paper
• Bone marrow stromal cells for repair of the spinal cord: towards clinical application.

  2006cites this paper
• EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.

  2006cites this paper
• Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

  2006cites this paper
• [Small cell lung cancer (CPC). Small cell bronchial carcinoma: therapeutic management].

  2006cites this paper
• 100 years of lung cancer.

  2006cites this paper
• Cancers bronchiques à petites cellules : comment améliorer les résultats du traitement et soutenir la réponse obtenue ?

  2006cites this paper
• CÁNCER DE PULMÓN MICROCÍTICO: REVISIÓN

  2006cites this paper
• Le cancer bronchique à petites cellules est-il une maladie orpheline ?

  2006cites this paper
• Bone Marrow Stromal Cells for Repair of the Spinal Cord: Towards Clinical Application

  2006cites this paper
• Reversal of resistance to oxazaphosphorines.

  2006cites this paper
• High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults.

  2006cites this paper
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

  2006cites this paper
• Actualización en el tratamiento sistémico del carcinoma microcítico de pulmón

  2005cites this paper
• Can dose-dense chemotherapy improve outcome in patients with better-prognosis small-cell lung cancer?

  2005cites this paper
• Ifosfamide, carboplatin, and etoposide with midcycle vincristine versus standard chemotherapy in patients with small-cell lung cancer and good performance status: clinical and quality-of-life results of the British Medical Research Council multicenter randomized LU21 trial.

  2005cites this paper
• Metabolism and Transport of Oxazaphosphorines and the Clinical Implications

  2005influential citation
• Management of small-cell lung cancer.

  2004cites this paper